Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,376,000.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Timothy Rolph sold 25,000 shares of the business’s stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $55.04, for a total value of $1,376,000.00. Following the completion of the transaction, the insider now directly owns 169,721 shares of the company’s stock, valued at approximately $9,341,443.84. This trade represents a 12.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Timothy Rolph also recently made the following trade(s):

• On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.49, for a total value of $668,625.00.
• On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $43.43, for a total value of $542,875.00.
• On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.03, for a total transaction of $256,437.50.
• On Monday, April 7th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $35.88, for a total transaction of $224,250.00.

Akero Therapeutics Stock Up 0.8%

AKRO opened at $54.71 on Tuesday. The company has a market cap of $4.36 billion, a PE ratio of -14.59 and a beta of -0.16. Akero Therapeutics, Inc. has a twelve month low of $21.02 and a twelve month high of $58.40. The company has a 50-day moving average price of $42.56 and a 200 day moving average price of $39.79. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of ($1.01) by $1.91. Sell-side analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Trading of Akero Therapeutics

Several large investors have recently made changes to their positions in AKRO. Northwest & Ethical Investments L.P. purchased a new position in Akero Therapeutics in the 1st quarter valued at $32,000. GF Fund Management CO. LTD. acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $41,000. Sterling Capital Management LLC lifted its stake in shares of Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after buying an additional 1,582 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company’s stock worth $67,000 after acquiring an additional 390 shares during the last quarter. Finally, Quarry LP acquired a new position in Akero Therapeutics during the fourth quarter worth about $83,000.

Analysts Set New Price Targets

Several research firms recently commented on AKRO. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Bank of America raised their target price on Akero Therapeutics from $63.00 to $64.00 and gave the company a “buy” rating in a research report on Tuesday, May 27th. Citigroup reduced their price target on Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Finally, HC Wainwright raised their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a report on Monday, March 3rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics currently has a consensus rating of “Buy” and an average target price of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.